What Does Johnson & Johnson's Vaccine Pause Mean for You?

The potential side effect is a blood clot in the veins that drain blood from the brain. This is called central venous sinus thrombosis. In the vaccine-associated cases of this, platelets in blood, which are important for making clots, have been lower than normal. While researchers do not know for certain why this is so, platelet counts could be lower perhaps because they have been used up making these clots.

About one in a million: Six cases out of the 6.8 million doses of the J&J vaccine administered in the U.S. These six cases all occurred in women ages 18 to 48, and from six to 13 days after vaccination. That's about half as likely as getting struck by lightning in a year.

What is being determined now is what is the normal background number of cases we might see in the general population without the vaccine as a factor. This will make it possible to determine if the clotting problem is a vaccine side effect or not.

The CDC and FDA are recommending that people who have received the J&J vaccine within the last three weeks who develop severe headache, abdominal pain, leg pain or shortness of breath should contact their health care provider.

Fortunately, this type of blood clot is treatable with the use of blood thinners or anticoagulants. If a patient has low platelets, however, a doctor would not prescribe the widely used anticoagulant heparin but instead another kind of blood thinner. Untreated, these blood clots can be fatal.

Because of this rare occurrence, even though it has not been shown to be due to the vaccine, the CDC and FDA have recommended a pause in use of the J&J vaccine until these cases can be further reviewed.

The CDC will convene a meeting of the Advisory Committee on Immunization Practices April 14, 2021. The ACIP is an independent board of 15 scientific and medical experts selected by the health and human services secretary that advises the CDC on vaccines for children and adults. People with ties to vaccine manufacturers are excluded from the ACIP membership because of potential conflict of interest.

The ACIP will review the available evidence and make recommendations to the CDC, based to a great extent on the likelihood that the complication is vaccine related.

A similar rare problem of blood clotting with low platelets in the cerebral venous sinus and also in the abdominal veins and arteries has been seen in connection with the use of the AstraZeneca COVID-19 vaccine used in Europe. There, 182 cases were reported in 190 million doses — again, roughly 1 in 1 million people vaccinated. The European Medicines Agency investigated this and concluded that central venous sinus thrombosis with low platelets should be listed as a  possible "very rare side effect" of the AstraZeneca vaccine.

On April 13, 2021, Johnson & Johnson announced it is delaying the rollout of its vaccine in Europe in response to the U.S. review.

The U.S. has a total of three vaccines authorized under emergency use authorization for COVID-19, and this side effect has not been observed in the other two vaccines, developed by Moderna and Pfizer. The Moderna and Pfizer vaccines do not use the same technology used in the J&J and AstraZeneca vaccines. So vaccination against COVID-19 can continue, while efforts are made to determine if the clotting disorder is related by chance or a true, but extremely rare, side effect of the J&J vaccine.

I believe it is a testament to the emphasis by the CDC and FDA on vaccine safety that J&J vaccinations have been paused while this is studied by independent scientists and medical experts.

This article is republished from The Conversation under a Creative Commons license. You can find the original article here.

William Petri is a professor of medicine at the University of Virginia. He receives funding the National Institute of Health, the Gates Foundation, PBM C19 and Regeneron Inc.